SPDR S&P Biotech ETF
707 hedge funds and large institutions have $7.15B invested in SPDR S&P Biotech ETF in 2023 Q2 according to their latest regulatory filings, with 70 funds opening new positions, 183 increasing their positions, 271 reducing their positions, and 67 closing their positions.
New
Increased
Maintained
Reduced
Closed
more ownership
Funds ownership: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
17% less funds holding in top 10
Funds holding in top 10: 23 → 19 (-4)
32% less repeat investments, than reductions
Existing positions increased: 183 | Existing positions reduced: 271
36% less call options, than puts
Call options by funds: $1.15B | Put options by funds: $1.8B
Holders
707
Holding in Top 10
19
Calls
$1.15B
Puts
$1.8B
Top Buyers
| 1 | +$431M | |
| 2 | +$137M | |
| 3 | +$47.1M | |
| 4 |
Jane Street
New York
|
+$29M |
| 5 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
+$26M |
Top Sellers
| 1 | -$239M | |
| 2 | -$204M | |
| 3 | -$142M | |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$142M |
| 5 |
Citigroup
New York
|
-$117M |